Cytokinetics, Incorporated
CYTK
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin actā¦ read more
Healthcare
Biotechnology
20 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$48.72
Price+1.85%
$0.89
1Y
Price
Market Cap
$5.829b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-14838.8%
EBITDA Margin-16244.7%
Net Profit Margin-15299.8%
Free Cash Flow MarginRevenue
$85.738m
-50.2%
1y CAGR-36.0%
3y CAGR-20.4%
5y CAGREarnings
-$606.311m
-0.8%
1y CAGR-32.5%
3y CAGR-36.3%
5y CAGREPS
-$5.11
+0.9%
1y CAGR-21.0%
3y CAGR-21.7%
5y CAGRBook Value
-$368.720m
$1.226b
Assets$1.594b
Liabilities$858.058m
DebtDebt to Assets
70.0%
-1.6x
Debt to EBITDAFree Cash Flow
-$440.477m
-1.2%
1y CAGR-32.5%
3y CAGR-2268.1%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company